FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201169741> ?p ?o ?g. }

• W3201169741 abstract "Translational research on immune checkpoint inhibitors (ICIs) has been underway. However, in the unselected population, only a few patients benefit from ICIs. Therefore, screening predictive markers of ICI efficacy has become the current focus of attention. We collected mutation and clinical data from an ICI-treated non-small cell lung cancer (NSCLC) cohort. Then, a univariate Cox regression model was used to analyze the relationship between tumor necrosis factor α signaling mutated (TNFα-MT) and the prognosis of immunotherapy for NSCLC. We retrospectively collected 36 NSCLC patients (local-cohort) from the Zhujiang Hospital of Southern Medical University and performed whole-exome sequencing (WES). The expression and mutation data of The Cancer Genome Atlas (TCGA)-NSCLC cohort were used to explore the association between TNFα-MT and the immune microenvironment. A local cohort was used to validate the association between TNFα-MT and immunogenicity. TNFα-MT was associated with significantly prolonged overall survival (OS) in NSCLC patients after receiving immunotherapy. Additionally, TNFα-MT is related to high immunogenicity (tumor mutational burden, neoantigen load, and DNA damage response signaling mutations) and enrichment of infiltrating immune cells. These results suggest that TNFα-MT may serve as a potential clinical biomarker for NSCLC patients receiving ICIs." @default.
• W3201169741 created "2021-09-27" @default.
• W3201169741 creator A5020386057 @default.
• W3201169741 creator A5036964633 @default.
• W3201169741 creator A5038133280 @default.
• W3201169741 creator A5047941899 @default.
• W3201169741 creator A5069143799 @default.
• W3201169741 creator A5071931173 @default.
• W3201169741 creator A5082582836 @default.
• W3201169741 date "2021-09-16" @default.
• W3201169741 modified "2023-10-18" @default.
• W3201169741 title "TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer" @default.
• W3201169741 cites W1910012553 @default.
• W3201169741 cites W1982488143 @default.
• W3201169741 cites W2004709950 @default.
• W3201169741 cites W2010457001 @default.
• W3201169741 cites W2035618305 @default.
• W3201169741 cites W2042797183 @default.
• W3201169741 cites W2049553585 @default.
• W3201169741 cites W2066671159 @default.
• W3201169741 cites W2088456011 @default.
• W3201169741 cites W2097855813 @default.
• W3201169741 cites W2106511606 @default.
• W3201169741 cites W2107296569 @default.
• W3201169741 cites W2114843025 @default.
• W3201169741 cites W2118342755 @default.
• W3201169741 cites W2122385884 @default.
• W3201169741 cites W2124427232 @default.
• W3201169741 cites W2132532093 @default.
• W3201169741 cites W2156353875 @default.
• W3201169741 cites W2201214180 @default.
• W3201169741 cites W2220506303 @default.
• W3201169741 cites W2222106751 @default.
• W3201169741 cites W2230320310 @default.
• W3201169741 cites W2280957887 @default.
• W3201169741 cites W2302719382 @default.
• W3201169741 cites W2401056916 @default.
• W3201169741 cites W2522409468 @default.
• W3201169741 cites W2527905628 @default.
• W3201169741 cites W2532791459 @default.
• W3201169741 cites W2547310148 @default.
• W3201169741 cites W2567564314 @default.
• W3201169741 cites W2587048937 @default.
• W3201169741 cites W2602840230 @default.
• W3201169741 cites W2609243345 @default.
• W3201169741 cites W2614965956 @default.
• W3201169741 cites W2622499649 @default.
• W3201169741 cites W2737082469 @default.
• W3201169741 cites W2760942750 @default.
• W3201169741 cites W2770893462 @default.
• W3201169741 cites W2779221466 @default.
• W3201169741 cites W2781525129 @default.
• W3201169741 cites W2788142646 @default.
• W3201169741 cites W2788431960 @default.
• W3201169741 cites W2795176800 @default.
• W3201169741 cites W2796207838 @default.
• W3201169741 cites W2886498337 @default.
• W3201169741 cites W2886753634 @default.
• W3201169741 cites W2889242099 @default.
• W3201169741 cites W2891551818 @default.
• W3201169741 cites W2896872272 @default.
• W3201169741 cites W2899638370 @default.
• W3201169741 cites W2909610569 @default.
• W3201169741 cites W2946126594 @default.
• W3201169741 cites W2949487479 @default.
• W3201169741 cites W2956987968 @default.
• W3201169741 cites W2962965662 @default.
• W3201169741 cites W2972582992 @default.
• W3201169741 cites W2975736787 @default.
• W3201169741 cites W2988046914 @default.
• W3201169741 cites W2989784033 @default.
• W3201169741 cites W2989811984 @default.
• W3201169741 cites W2990431514 @default.
• W3201169741 cites W3016121647 @default.
• W3201169741 cites W3036531813 @default.
• W3201169741 cites W3039619788 @default.
• W3201169741 cites W3040813705 @default.
• W3201169741 cites W3041538945 @default.
• W3201169741 cites W3047306469 @default.
• W3201169741 cites W3048754226 @default.
• W3201169741 cites W3048849240 @default.
• W3201169741 cites W3083483552 @default.
• W3201169741 cites W3089009365 @default.
• W3201169741 cites W3112913477 @default.
• W3201169741 cites W3193938634 @default.
• W3201169741 cites W3194506780 @default.
• W3201169741 cites W3196107865 @default.
• W3201169741 doi "https://doi.org/10.3389/fimmu.2021.667875" @default.
• W3201169741 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8481577" @default.
• W3201169741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34603277" @default.
• W3201169741 hasPublicationYear "2021" @default.
• W3201169741 type Work @default.
• W3201169741 sameAs 3201169741 @default.
• W3201169741 citedByCount "9" @default.
• W3201169741 countsByYear W32011697412022 @default.
• W3201169741 countsByYear W32011697412023 @default.
• W3201169741 crossrefType "journal-article" @default.
• W3201169741 hasAuthorship W3201169741A5020386057 @default.
• W3201169741 hasAuthorship W3201169741A5036964633 @default.
• W3201169741 hasAuthorship W3201169741A5038133280 @default.

• next